2026 International Congress » Parkinson’s Disease: Pharmacology and Medical Management

“Most of us are improvising with the work we are doing”: Perspectives of health and social care professionals in Ghana and Kenya on mobility management for Parkinson’s disease

R. Mc Ardle, J. Lumsdon, B. Mghendi, E. Ame-Bruce, W. Animdife, M. Agoriwo, S. Del Din, M. Cham, A. Akpalu, L. Rochester, K. Brittain, R. Walker, N. Fothergill-Misbah (Newcastle Upon Tyne, United Kingdom)

A case of monotherapy with intracerebroventricular anaerobic dopamine allows complete control of Parkinson’s disease symptoms

C. Moreau, F. Marchand, J. Bene, C. Leclercq, V. Foutel, M. Fisichella, D. Devos (Lille, France)

A Case Report: Optimising Motor and Non-Motor Control in Advanced Parkinson’s Disease: The Role of Foslevodopa/Foscarbidopa After Deep Brain Stimulation

J. Wong, S. Williams, M. Lubomski (St Leonards, Australia)

A Cerner-based Electronic Prescribing and Medicines Administration (EPMA) Parkinson’s Medicines Care Plan Reduces Time-Critical Medication (TCM) Errors.

T. Lessware, R. Lal, M. Andrews, D. Trivedi, J. Mathews, E. Bhadra, C. Budu, D. Gallagher, A. Noyce, T. Boyle (London, United Kingdom)

Aerva Lanata Decoction Alleviates Neuroinflammation And Locomotor Dysfunction In Parkinson Model

G. Chandran, B. Ramachandra (Mysuru, India)

Ambulatory PEMF stimulation using the DCcure device improves rest and postural tremor in patients with PD

I. Urman, M. Scheinowitz, R. Djaldetti (Petah Tiqva, Israel)

Assessing Concordance Between Clinical judgment And 5-2-1 Criteria In Advanced Parkinsons Disease

A. Subramaniam, M. Mann, B. Mohamed, J. Adenwalla (Cardiff, United Kingdom)

Baseline Factors Associated with Sublingual Apomorphine Film Maintenance Dose

J. Kassubek, J. Schwarz, L. López Manzanares, J. Reis, H. C. Brigas, C. Denecke-Muhr, J. Holenz (Ulm, Germany)

Beyond Motor Fluctuations: Non-Motor and Quality-Of-Life Outcomes with Subcutaneous Foslevodopa/Foscarbidopa Infusion in Real-World Practice

V. Pérez-Del-Olmo, B. De-La-Casa-Fages, JR. Pérez-Sánchez, A. Bonilla-Tena, A. Contreras-Chicote, E. Luque-Buzo, E. González-Turiño, FJ. Grandas-Pérez (Madrid, Spain)

Beyond Motor Outcomes: Health Literacy, Medication Adherence, and Quality of Life in Parkinson’s Disease Patients Undergoing the Levodopa Challenge Test

M. da Silva, M. Tosin, L. Silveira-Moriyama (Campinas, Brazil)

Biochemical and Nutritional Changes During Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson’s Disease: Findings from an Observational Cohort

O. Phokaewvarangkul, N. Rattanapitak, P. Kuwattanasuchati, R. Bhidayasiri (Bangkok, Thailand)

Brain-targeted dual-loaded extracellular vesicles enable PROTAC-mediated LRRK2 degradation in Parkinson’s disease

JEK. Kim, YH. Yang, OYB. Bang (Seoul, Republic of Korea)

Can a slogan poster featuring the patient’s primary physician help improve gait and prevent falls at home in patients with Parkinson’s disease?

Y. Okuma (Izunokuni, Japan)

Clinical Features and Trajectories Related to Entacapone Use in Parkinson’s Disease: insights from the French NS Park Cohort

S. Gallo, P. Bastos, JE. Timmermann, M. Fabbri, B. Morlaes, O. Rascol (Toulouse, France)

Clinical Impact of Nicotine in Parkinson’s Disease: Evidence from Randomized Controlled Studies

J. Pitton Rissardo, J. Patino, A. Fornari Caprara, A. Mcgarry, I. Walker (Camden, USA)

Clinical Underestimation of Wearing-Off in Parkinson’s Disease: Patient-Reported Outcomes Versus Clinical Assessment and Impact on Quality of Life

M. Acharya, A. Debnath (Kharagpur, India)

Combination Device-aided therapy in Parkinson’s Disease

S. Garg, G. Chavira-Hernandez, R. Munhoz, T. Mestre (Ottawa, Canada)

Comparison Of Levodopa Dose Frequency And Parkinson’s Kinetigraph Metrics For Screening Advanced Parkinson’s Disease

N. Ullah, H. Renduchintala, B. Mohamed, J. Adenwalla (Cardiff, United Kingdom)

Consistent Motor Benefit of Safinamide across Clinically Relevant Subgroups in Japanese Patients with Parkinson’s Disease: A 24-Week Real-World Study

Y. Tsuboi, Y. Kogo, T. Ishida, K. Koizumi, M. Ishii (Tokyo, Japan)

Continuous Subcutaneous Foslevodopa/Foscarbidopa After Deep Brain Stimulation or Levodopa–Carbidopa Intestinal Gel: A Case Series in Advanced Parkinson’s Disease

Y. Abdelmajid, M. Thomas, K. Waqar, E. de Freitas, R. Cabrito, R. Battah, A. Anjum, S. Om Mittal (Abu Dhabi, United Arab Emirates)

Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in Advanced Parkinson’s Disease: Results from a Prospective Real-world Study

G. Pinola, V. Leta, M. Tosi, C. Leuzzi, F. Colucci, G. Gaudiano, A. Braccia, F. Pirone, S. Rinaldo, R. Cancilla, N. Golfrè Andreasi, L. Romito, G. Devigili, R. Cilia, AE. Elia, R. Eleopra (Milano, Italy)

Continuous subcutaneous levodopa infusion in advanced Parkinson’s disease: a descriptive real-world cohort study

P. Prendes Fernandez, P. Tartiere Gonzalez, E. Suarez Sanmartin, C. Garcia Fernandez, L. Gonzalez Alvarez, M. Blazquez Estrada (Oviedo, Spain)

Continuous Subcutaneous Levodopa Therapy Improves Motor Fluctuations and Quality of Life in Parkinson’s Disease: Evidence from Meta-analysis of Clinical Trials

K. Sarhan (Mansoura, Egypt)

Deciphering the NLRP3-Driven Olfactory–Brain Axis in Parkinson’s disease: Neuroprotective Role of Betulin

A. Kumar, V. Malhotra (Ahamdabad, India)

Demographic And Clinical Characteristics Of Advanced Parkinson’s Disease Patients Receiving Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) In The ELEGANCE Study: An Updated Interim Analysis

S. Singh, N. Smith, B. Amlani (Reading, United Kingdom)

Device-aided Therapies are Associated with Significantly Greater Improvement in Quality of Life in Younger Patients Earlier Within Advanced Parkinson’s Disease

D. Santos García, á. Solleiro Vidal, L. López Manzanares, S. Martí Matínez, J. González Ardura, J. Gómez Esteban, T. Delgado, G. González Ortega, E. Cubo, B. Solano, AB. Perona-Moratalla, S. Escalante, á. Monterde Ortega, MP. Gil Martín, R. López Blanco, C. Borrué Fernández, I. Martínez Torres, P. García Ruíz, I. Pareés Moreno, C. Delgado Suárez (A Coruña, Spain)

Differences in Levodopa Equivalent Daily Dose (LEDD) Based on Disease Duration in Parkinson’s Disease Patients at RSCM – A Tertiary National Referral Hospital

F. Abdat, A. Tiksnadi, D. Tungjungsari (Jakarta, Indonesia)

Does Knowing More Mean Tolerating More? Satisfaction with Medication Information and Levodopa Dosage in Parkinson’s Disease

M. da Silva, M. Tosin, L. Silveira-Moriyama (Chicago, USA)

Dopaminergic Medication Changes Following LFP-Guided Deep Brain Stimulation Programming in Parkinson’s Disease: A Single-Centre Audit

M. Pagan, F. Kotsi, M. Boca (Gloucester, United Kingdom)

Dual device-aided therapy in advanced Parkinson’s Disease: combining bilateral deep brain stimulation and continuous subcutaneous foslevodopa/foscarbidopa Infusion

C. Ribacoba Díaz, A. Fernández Revuelta, A. Aldaz Burgoa, E. López Valdés, R. García-Ramos García (Madrid, Spain)

Early dopaminergic treatment patterns and 5-year survival in Parkinson’s disease: a nationwide observational study

S. Lee, J. Lee, J. Bae, Y. Cho, Y. Hwang, K. Park, J. Oh, J. Kang (Jeju, Republic of Korea)

Effectiveness of Switching from Levodopa-Carbidopa Intestinal Gel to Levodopa-Carbidopa-Entacapone Intestinal Gel in Patients with Refractory Biphasic and Peak-of-Dose Dyskinesia

R. Garcia-Ramos Garcia, A. Fernandez Revuelta, A. Aldaz Burgoa, C. Ribacoba Diaz, A. Alonso Cánovas, I. Parees Moreno, C. Moreno Lopez, JC. Martinez Castrillo (Madrid, Spain)

Effects of Modafinil on Motor and Non‑Motor Outcomes in Parkinson’s Disease: A Meta‑Analysis of Randomized, Placebo‑Controlled Trials

A. Lin, J. Rissardo, J. Patino, A. Caprara, A. Mcgarry, I. Walker (Cincinnati, USA)

Efficacy and Safety of GLP-1 Receptor Agonists in Parkinson’s Disease: A Meta-Analysis Integrating the 96-Week Phase 3 Exenatide Trial Results

K. Sarhan (Mansoura, Egypt)

Efficacy and Safety of Inhaled and Sublingual Apomorphine for On-Demand Treatment of OFF Episodes in Parkinson’s Disease: A Meta‑Analysis of Randomized Placebo‑Controlled Trials

J. Martinez-Lemus, J. Rissardo, J. Patino, A. Caprara, A. Mcgarry, I. Walker (Camden, USA)

Efficacy and Safety of Mesdopetam (IRL790) for Levodopa Induced Dyskinesia in Parkinson’s Disease: A Meta analysis of Randomized Controlled Trials

A. Achuthaprasad, J. Rissardo, J. Patino, A. Caprara, A. Mcgarry, I. Walker (Houston, USA)

Efficacy and Safety of Muscle Afferent Block for Camptocormia in Parkinson’s Disease

S. Horie, K. Matsuura, K. Sakae, A. Shindo (Tsu, Mie, Japan)

Efficacy of botulinum toxin treatment for cervical dystonia associated with Parkinson’s disease: A case series.

S. Mian, R. Goel, E. Roddy, V. Holiday, P. Hedera (Louisville, USA)

Efficacy of Opicapone in Early Motor Fluctuations in Parkinson’s Disease: A Comparison of Early versus Later Initiation

JJ. Ferreira, F. Stocchi, A. Antonini, O. Rascol, G. Ebersbach, J. Kulisevsky, MM. Fonseca, D. Ramos, J-F. Rocha, HC. Brigas, J. Holenz, W. Poewe (Lisbon, Portugal)

Evaluating the Conversion of Immediate-Release and/or Extended-Release Levodopa to IPX203 in Patients with Parkinson’s Disease

L. Poon, A. Lee, D. Lee, T. Chiao, T. Stiep (Stockton, USA)

External Validation of Reported Clinical Predictors of Levodopa-Related Adverse Drug Reactions in Parkinson’s Disease

L. Helling, R. Weijer, J. Swen, S. Böhringer, J. van Hilten, D. Hepp (Leiden, Netherlands)

First Reported Experience of Dual Therapy With Deep Brain Stimulation and Foslevodopa/Foscarbidopa Subcutaneous Infusion

E. Casas, I. Muro, P. Lorenzo, L. Lopez-Manzanares (Madrid, Spain)

From Roots to Relief: A Systematic Review of Herbal Medicines in Parkinson’s Management

N. Sukmueng, O. Phokeawvarangkul, R. Bhidayasiri (Bangkok, Thailand)

From Vision to Reality: Nursing Driven Implementation, Policy, and Safety Framework for Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in a Tertiary Movement Disorder Centre

E. de Freitas, S. Mittal (Abu Dhabi, United Arab Emirates)

Harnessing the Local Wisdom of Central Kalimantan’s Eleutherine palmifolia (Dayak Onion) in Parkinson’s Disease Therapy: A Molecular Docking and Ethnopharmacological Study”

NIN. Surbakti, LIF. Sayyidinoor, YAN. Antonio, RIF. Akbar (Palangka Raya, Indonesia)

Hot and Fast but Still Parkinson’s Disease: A Case of Dyskinesia-Hyperpyrexia Syndrome

T. Coradine, P. Fraiman, D. Salarini, C. Pereira, K. Couto, G. Chung, M. Soares (São Paulo, Brazil)

Icariin, a Flavonoid from Epimedium, Confers Dopaminergic Neuroprotection and Neuromodulation in MPTP-Induced Parkinsonian Rats

A. Singh (Allahabad, India)

Immunological principles of levodopa therapy in Parkinson’s disease

N. Naimov, B. Muminov, S. Jumanazarova, R. Matmurodov, H. Daminova (Tashkent, Uzbekistan)

Impact of Helicobacter pylori Eradication on MDS-UPDRS Part III Motor Score in Patients With Parkinson’s Disease A Prospective Cohort Study in Northern Mexico

S. Murillo Quintana, D. Sanchez Galvan (Torreon, Mexico)

Impact of Vitamin D Supplementation on Cognitive Function, Quality of Life, and Dyskinesia in Parkinson’s Disease: A Systematic Review and Meta-Analysis

C. Perera, A. Pathirage, K. Muhunthan, S. Jayakody, C. Arambepola, T. Chang (Colombo, Sri Lanka)

Improvement in Time Spent in OFF State and In the Functional Impact of Motor Fluctuations After Initiation with COMT Inhibitors in Parkinson’s Disease Patients with Early Wearing-Off: Results from the REONPARK Study

L. López-Manzanares, B. Solano, T. Delgado, J. García-Caldentey, A. Rodriguez-Sanz, R. García-Ramos, M. Rodriguez-de Miguel, I. Tegel, D. Magalhāes, J. Holenz (Girona, Spain)

Improvement of Wearing‑Off Symptoms After Initiation of COMT Inhibitors in Parkinson’s Disease patients with early motor fluctuations: Results from the 12 months interim analysis of REONPARK Study

L. López-Manzanares, M. Cerdán, I. Gaston, R. Vázquez, B. Vives, M. Carmona, M. Rodriguez-de Miguel, I. Tegel, D. Magalhāes, J. Holenz (Madrid, Spain)

Inpatient Titration Protocol and Practical Implementation of Continuous Subcutaneous Foslevodopa/Foscarbidopa: Lessons from 28 Consecutive Cases

Y. Abdelmajid, M. Thomas, K. Waqar, E. de Freitas, R. Cabrito, R. Battah, A. Anjum, S. Mittal (Abu Dhabi, United Arab Emirates)

Intestinal Levodopa Infusion Therapies in Advanced Parkinson’s Disease: A 6-Month Prospective Cohort Study

I. Straka, Z. Andre, S. Bilek, P. Valkovic, Z. Kosutzka, M. Minar (Bratislava, Slovakia)

Ketogenic Diet and Motor Outcomes in Parkinson’s Disease: A Meta-analysis of Randomized Trials

A. Fornari Caprara, J. Pitton Rissardo, J. Patino, A. Mcgarry, I. Walker (Camden, USA)

L-DOPA Metabolism as a Function Related to the Potency of iPSC-Derived Dopaminergic Progenitor cells

S. Hiramatsu, C. Naito, M. Fujiwara, T. Yamashita, K. Watanabe, T. Yamada, R. Yamaguchi (Kobe, Japan)

Levodopa-Induced Dyskinesias in Patients with Parkinson’s Disease in the Uzbek Population

G. Isroilova, Z. Sayfitdinkhuzhaev (Tashkent, Uzbekistan)

Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) Provides Sustained Improvement In Quality Of Life In Advanced Parkinson’s For Up To Two Years

S. Singh, N. Smith, B. Amlani (Reading, United Kingdom)

Levodopa–Entacapone–Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: a Four-Year Real-Life Experience

J. Szasz, V. Constantin, K. Orban Kis, R. Szasz, S. Bataga, R. Neagoe, M. Ciorba, K. Kelemen, I. Mihaly, K. Biro, S. Szatmari (TARGU MURES, Romania)

Long-term Safety of Opicapone in Parkinson’s Disease Patients with First Signs of Wearing-off

JJ. Ferreira, F. Stocchi, A. Antonini, O. Rascol, G. Ebersbach, J. Kulisevsky, N. Pavese, G. Hoglinger, D. Ramos, J-F. Rocha, HC. Brigas, J. Holenz, W. Poewe (Lisboa, Portugal)

Low-dose ketamine reduces dopamine 2 receptor-like agonist-induced dyskinesia in a preclinical model

T. Falk, R. Parmar, J. Meredith, J. Castro, E. Smith, M. Bartlett, S. Sherman (Tucson, USA)

Medical Management of Late-stage Parkinson’s Disease – a Cross-sectional, Multinational Survey

C. Pallauf, C. Weck, C. Brandl, S. Lorenzl (Salzburg, Austria)

Medication Burden and Associated Challenges for People with Parkinson’s: A Survey of 359 UK Patients

S. Jones, D. van Wamelen, S. Chapman, J. Patel (London, United Kingdom)

Modulation of Excitatory/Inhibitory Neurotransmission via Targeting GABAA-Gephyrin Signaling: Integrated In-Silico, In-Vitro, and In-Vivo Evidence in Parkinson’s Disease Models

S. Chib (Bathinda, India)

Multidisciplinary Care Preserves Function and Quality of Life After Nursing Home Placement in Late-Stage Parkinson’s Disease: A Prospective Cohort Study

Y. Kajiyama, A. Saito, R. Satake, Y. Kutoku, K. Oku, T. Ito, M. Yoshimura, J. Hirata, F. Hyodo, N. Tsujiuchi, M. Mitsuishi, M. Kurokawa, D. Kimura, T. Yasuda, M. Mihara (Okayama, Japan)

Nine-Year Outcome of MRI Guided Focused Ultrasound Thalamotomy in Essential Tremor Patients

I. Schlesinger, M. Nassar, A. Sinai, I. Senderova, M. Katson, M. Constantinescu, M. Zaaroor, L. Lev Tov (Haifa, Israel)

Opicapone Co-administration Allows Significant Flow Reduction in Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion: A Real-World Case Series

G. Tabar Comellas, N. Lopez Ariztegui, M. Morales Casado (TOLEDO, Spain)

Oral D1-like/D2-like Receptor Agonist, Lu AF28996, Provides Robust Antiparkinsonian Efficacy with Reduced Dyskinesia in the MPTP-Macaque Model

H. Lindgren, E. Bezard (Copenhagen, Denmark)

Peripheral neuropathy (NP) in advanced Parkinson’s disease (PD) patients treated with continuous subcutaneous foslevodopa/foscarbidopa (fLD/fCD)

H. Salhi, A. Gravier, V. Garbage, B. Cormier, A. Dormeuil, A. Petit, A. Zayed, V. Perrain, T. Gendre, P. Remy (Creteil, France)

Personalised Selection Of Device-Aided Infusion Therapies In Advanced Parkinson’s Disease: A European Expert Delphi Consensus

V. Correa-Gallego, J. Castrillo, K. Chaudhuri, T. Henriksen, W. Jost, N. Kovács, O. Rascol, B. Popescu (Reading, United Kingdom)

Polypharmacy and its Impact in Individuals with Parkinson’s Disease: Theory- and Data-Driven Approaches

E. Nguyen, S. Maji, B. Klinedinst, N. Meier (Irvine, USA)

Postural Disorders in Parkinson’s Disease: The Role of Botulinum Toxin – A French prospective cohort

M. Pougeon, C. Tourlet, S. Grimaldi, A. Eusebio, JP. Azulay, F. Fluchere (Marseille, France)

Predictors of Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Systematic Review and Meta-Analysis

A. Elsaid, H. Hussien, A. Hegazi (Dakahlia, Egypt)

Probiotic Y7 Intervention Is Associated with Improved Motor, Gut-Related, and L-DOPA-Related Outcomes in a Rat Model of Parkinson’s Disease

HY. Huang, TH. Yeh, SP. Tsao, DY. Wang, TJ. Chen (Taipei City, Taiwan)

Progression and disability in Parkinson’s disease: what else can be done?

S. Shtaimets, а. Agasheva, I. Zhukova, D. Novotnyy, N. Zhukova (Tomsk, Russian Federation)

Psychosis in Parkinson’s Disease Patients Treated with Continuous Subcutaneous Foslevodopa/Foscarbidopa: A Real-World Observational Study.

M. Angerri Nadal, C. Marzal Espi, R. Gomez Llopico, S. Jauma Classen, M. Calopa Garriga, H. Bejr-Kasem Marco (Barcelona, Spain)

Real-World Clinical Experience With Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion In Advanced Parkinson’s Disease Patients With Mild Cognitive Impairment And History Of Psychosis

MN. Afkir Ortega, E. Navarro Mocholi, I. Sastre Bataller, M. Campins Romeu, C. Morata Martínez, R. Baviera Muñoz, J. Perez Garcia, I. Martinez Torres (Valencia, Spain)

Real-world database analysis of new-onset hypotension and medications for orthostatic hypotension prescribing patterns in patients with Parkinson’s Disease receiving MAO-B Inhibitors and levodopa in Japan

M. Nagai, R. Ando, K. Sasaki, Y. Tomita, K. Daidoji, Y. Kogo, T. Ishida (Tokyo, Japan)

Real-World Experience with Continuous Subcutaneous Foslevodopa/Foscarbidopa (FLC/FCD) in Advanced Parkinson’s Disease: A Single-Centre Cohort Study

K. Waqar, M. Thomas, Y. Abdelmajid, E. Freitas, R. Cabrito, RH. Battah, A. Anjum, SH. Mittal (Abu Dhabi, United Arab Emirates)

Real-world variability in dosing of continuous subcutaneous foslevodopa/foscarbidopa infusion in advanced Parkinson’s disease: evidence from a single-center cohort

I. Murasan, R. Margarit, R. Radu, L. Ungureanu, S. Berzunteanu, A. Drujescu, D. Batrinu, R. Chiujdea, R. Ilea, S. Diaconu, C. Falup-Pecurariu (Brasov, Romania)

Reduction in Dopaminergic Medication in Patients with Parkinson’s Disease Treated with Continuous Apomorphine Infusion versus Subthalamic Nucleus Deep Brain Stimulation: A Cohort Study

L. Reyes, C. Martínez, J. Fonseca, F. Castro, A. Calderon, C. Ramirez (México City, Mexico)

Remaining unmet needs in Essential Tremor and Parkinson’s Disease: European Neurologists’ Assessments of Pharmacologic Response and Advanced Therapy Use

N. Kaempf, á. Sánchez Fraga, C. Tengelin, P. Crivelli, K. Gant, C. Ferrer, A. Grinspan (Frankfurt am Main, Germany)

Repurposing Rifabutin for Neuro-Metabolic Disorders: AMPK-PGC-1α-Driven Mitochondrial Protection in Diabetes Associated Parkinsonism

M I. Khan, D. Ahmed (PRAYAGRAJ, India)

Risk Factors and Etiologies for Emergency Visit among Parkinson´s Disease Patients: a Narrative Review

R. Ojha, D. Ling, J. Ma, L. Wang, Y. Cao, J. Zhao, C. Yang (Kathmandu, Nepal)

Risk of Serotonin Syndrome in the Combined Use of Selective Monoamine Oxidase B Inhibitors and Serotonin-acting Antidepressants

RWH. Ho, SL. Ho, SYY. Pang (Hong Kong, Hong Kong)

Safety of Opicapone After 10 Years of Post-Marketing experience Worldwide

M. Vale, D. Lopes, H. Brigas, J. Holenz (Coronado, Portugal)

Screening the Neuroprotective Potential of Mushroom Extracts in In Vitro Models of Parkinson’s Disease

FD. Dustov, SB. Seo (Seoul, Republic of Korea)

Serum Zinc Reduction During Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson’s Disease

T. Utsunomiya, K. Matsuura, K. Miyashita, A. Shindo (Tsu, Mie, Japan)

Seven-Year Outcome of Focused Ultrasound Thalamotomy in Tremor Dominant Parkinson’s Disease Patients

M. Nassar, I. Senderova, M. Katson, A. Sinai, I. Schlesinger (Haifa, Israel)

Single centre experience with subcutaneous foslevodopa/foscarbidopa for GBA Parkinson’s disease

I. Muro, E. Casas, P. Lorenzo-Barreto, B. González, L. López-Manzanares (Madrid, Spain)

Sublingual apomorphine for parkinsonian tremor: Post-hoc analysis of pivotal trial data

H. S Dafsari, J. Reis, K. Strauß, H. C Brigas, C. Denecke-Muhr, I. Pijuan Jiménez, J. Holenz (Cologne, Germany)

Sublingual Apomorphine Tolerability in Clinical Practice: 18-months Post launch experience in Europe

J. Kassubek, R. García-Ramos, M. F. Gago, H. Brigas, C. Deneck-Muhr, D. Lopes, C. Meneses, J. Holenz (Ulm, Germany)

Switch from LCIG to LECIG in advanced Parkinson’s Disease: Real World Outcomes from a Single Centre

A. Aldaz Burgoa, A. Fernández Revuelta, C. Ribacoba Díaz, E. López Valdés, R. García-Ramos García (Madrid, Spain)

The Impact of Dopamine-Induced Impulse Control Disorders on Quality of Life in Young-Onset Parkinson’s Disease

S. Pokhriyal, A. Gupta (Delhi, India)

The ORCHESTRA Study Year 2: Practical Experiences With Foslevodopa/Foscarbidopa Treatment in Advanced Parkinson’s Disease in a Real-World Setting

T. Warneck, A. Der Plas, P. Schwingenschuh, A. Johansson, M. Simu, M. O’Meara, M. Li, T. Hancko, L. Bergmann, T. Musacchio, M. Südmeyer (Osnabrück, Germany)

The Potential of Mobile Applications to Enhance Self-Management in Parkinson’s Disease: A Systematic Review

F. Kanellos, S. Kontaxis, S. Kontogiannis, A. Ntanis, N. Kostikis, G. Rigas (Ioannina, Greece)

Therapeutic Potential of Probiotics for Clinical Management in Parkinson’s Disease: A Systematic Review

A. Suhendro, A. Kristanto, S. Trisnawati (Denpasar, Indonesia)

Toward Global Best Practices for Managing Skin Complications in Subcutaneous Infusion Therapy for Parkinson’s Disease: A Nursing and Advanced Practice Perspective

C. Goas, K. Papesh, N. Bryden, J. Nguyen, C. Kyinn, E. Edwards, N. Stapleton, B. Aparante, S. Gould, E. Zinn (Henderson, USA)

Translational evaluation of CSF as a relevant compartment for assessing target engagement of therapeutic anti–α-syn antibodies.

M. Ramos Vega, B. Ozgur, F. Sotty, A. Jensen, K. Bjerregaard-Andersen (Copenhagen, Denmark)

Various Levodopa Formulation effects on Local Field Potentials in Parkinson’s Disease

A. Madamangalam, J. Cagle, C. de Hemptinne, J. Wong (Gainesville, USA)

When Presynaptic Stimulation is Not Enough: Severe Biphasic Dyskinesia on LECIG Reversed by Postsynaptic Apomorphine Rescue

A. Alonso Cánovas, I. Parees Moreno, C. Moreno Lopez, A. Patiño Paton, EJ. Martinez Esteban, P. Perez Torre, JL. López Sendón, JC. Martinez Castrillo (Madrid, Spain)